William Moore, MD
Endocrinology, Diabetes & Metabolism · Birmingham, ALNPI 1457794570
Payments from drug & device makers
Across 692 payments — averaging $18.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$2K
- Bayer$1K
- Abbott$1K
- Boehringer Ingelheim$873
- Dexcom, Inc.$795
- plus $5K from 31 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 131 | $1,821 |
| Lilly USA, LLC | 102 | $1,609 |
| Bayer | 73 | $1,352 |
| Abbott | 50 | $1,061 |
| Boehringer Ingelheim | 54 | $873 |
| Dexcom, Inc. | 37 | $795 |
| Medtronic(2 entities) | 23 | $682 |
| Corcept Therapeutics | 30 | $629 |
| AstraZeneca | 32 | $591 |
| Amgen(2 entities) | 25 | $556 |
| Xeris Pharmaceuticals, Inc. | 22 | $370 |
| Sanofi-aventis U.S. LLC | 20 | $334 |
| IBSA Pharma Inc. | 12 | $266 |
| AbbVie | 14 | $264 |
| Tandem Diabetes Care, Inc. | 12 | $241 |
| BETA Bionics, Inc. | 5 | $241 |
| Insulet Corporation | 9 | $189 |
| Actelion Pharmaceuticals US, Inc. | 1 | $150 |
| Sequel Med Tech, LLC | 1 | $118 |
| Kowa Pharmaceuticals America, Inc. | 1 | $116 |
| Radius Health, Inc. | 5 | $90 |
| Novartis | 4 | $78 |
| Amarin Pharma, Inc. | 5 | $66 |
| GSK | 3 | $52 |
| Neurocrine Biosciences, Inc. | 2 | $48 |
| Merck | 3 | $48 |
| Pfizer | 3 | $45 |
| Averitas Pharma Inc. | 2 | $39 |
| Endogastric Solutions, Inc | 1 | $30 |
| Johnson & Johnson | 2 | $28 |
| Shire North American Group Inc | 2 | $26 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Ironshore Pharmaceuticals Inc. | 1 | $18 |
| Tolmar, Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
How this compares
$12,908 in reported general payments places this provider in the 65th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Birmingham
- William GarveyBirmingham$3.8M
- Fernando OvalleBirmingham$516K
- Ralph TeagueBirmingham$487K
- Amy WarrinerBirmingham$182K
- Edison GoncalvesBirmingham$142K
- Fernando BrilBirmingham$74K
- Tom VaughanBirmingham$68K
- Rodrigo ValderramaBirmingham$61K
- Janelle TownesBirmingham$56K
- Richard RosenthalBirmingham$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.